Company Overview of Wellcome Trust, Investment Division
Wellcome Trust, Investment Division is a private equity and venture capital firm specializing in equity financing in early stage companies, buyouts, absolute returns, and emerging markets. The firm also invests in venture capital funds and buyouts funds and also selectively invests in later-stage private companies. It prefers to invest in healthcare, life sciences, therapeutics, technologies, medical devices, financial services, and energy space. The firm typically invests in U.S. and Europe. It seeks to invest up to £10 million ($18.82 million) over the life of a company through initial and follow-on financings. The firm usually invests alongside venture capitalists that are represented on ...
215 Euston Road
London, NW1 2BE
Key Executives for Wellcome Trust, Investment Division
Chief Executive of Project Sigma
Managing Director and Member of Investment Committee
Chief Investment Officer and Member of Investment Committee
Compensation as of Fiscal Year 2016.
Wellcome Trust, Investment Division Key Developments
The Wellcome Trust Presents at BIO Trinity 2016, Apr-25-2016
Feb 13 16
The Wellcome Trust Presents at BIO Trinity 2016, Apr-25-2016 . Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom.
The Wellcome Trust Presents at The HedgeFund Intelligence European Summit 2015, Apr-28-2015 11:35 AM
Apr 16 15
The Wellcome Trust Presents at The HedgeFund Intelligence European Summit 2015, Apr-28-2015 11:35 AM. Venue: Palais de la Bourse, Paris, France. Speakers: Richard Walters, Investment Manager.
H. Lundbeck A/S Announces Research Partnership for Treatment of Brain Diseases Involving Seven Universities
Jan 9 15
H. Lundbeck A/S has announced a new public-private partnership involving seven universities, for the treatment of brain diseases. Lundbeck is involved in new research that will investigate a novel link that could show a relationship between the immune system and mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer's disease. This project, a public-private partnership also involving The Wellcome Trust, Cambridge University and pharmaceutical company Janssen, may be the first step towards a new and significantly improved treatment for a broad range of brain diseases. The main theory that the project will investigate is that the immune system can worsen brain diseases like depression and Alzheimer's disease. An imbalance in the immune system of the brain can drive a permanent and unhealthy neuro-inflammation - or inflammation in the brain - that can contribute to or cause brain diseases. This new project is a public-private partnership between Lundbeck and Janssen, and seven universities. The project has received a strategic award valued at approximately DKK 50m from the Wellcome Trust. The project consists of two parts. The team will begin by investigating the immune systems of people with treatment-resistant depression and Alzheimer's disease. In this phase, researchers will seek to more precisely establish the relationship between immune-related biomarkers found in blood and brain including cytokines, which are small proteins that play an important role in the regulation of the immune responses. The second part of the research program, which is reliant on the success of the first, will focus on small experimental medicine trials, using re-purposed anti-inflammatory drugs in patients who have been identified according to their specific immunological profile or 'phenotype'.
Similar Private Companies By Industry
Recent Private Companies Transactions